ATE531734T1 - Antikörper gegen p-selectin-glycoproteinliganden 1 (psgl-1) zur behandlung allergischer erkrankungen - Google Patents

Antikörper gegen p-selectin-glycoproteinliganden 1 (psgl-1) zur behandlung allergischer erkrankungen

Info

Publication number: ATE531734T1
Authority: AT; Austria
Prior art keywords: cell; psgl; antibodies; treatment; selectin glycoprotein
Prior art date: 2001-08-03

Application number

AT08012718T

Other languages

English (en)

Inventor

Lin Rong-Hwa

Wu Chung-Hsiun

Hsu Pei-Ling

Original Assignee

Abgenomics Cooeperatief U A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-03

Filing date

2002-03-13

Publication date

2011-11-15

2002-03-13 Application filed by Abgenomics Cooeperatief U A filed Critical Abgenomics Cooeperatief U A

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE531734T1 publication Critical patent/ATE531734T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Rheumatology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Microbiology (AREA)
Gynecology & Obstetrics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Oncology (AREA)

AT08012718T 2001-08-03 2002-03-13 Antikörper gegen p-selectin-glycoproteinliganden 1 (psgl-1) zur behandlung allergischer erkrankungen ATE531734T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31019601P	2001-08-03	2001-08-03
US10/051,497 US7744888B2 (en)	2001-08-03	2002-01-18	Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies

Publications (1)

Publication Number	Publication Date
ATE531734T1 true ATE531734T1 (de)	2011-11-15

Family

ID=26729479

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT02733839T ATE411045T1 (de)	2001-08-03	2002-03-13	Modulatoren des p-selectin-glycoprotein-liganden 1
AT08012718T ATE531734T1 (de)	2001-08-03	2002-03-13	Antikörper gegen p-selectin-glycoproteinliganden 1 (psgl-1) zur behandlung allergischer erkrankungen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT02733839T ATE411045T1 (de)	2001-08-03	2002-03-13	Modulatoren des p-selectin-glycoprotein-liganden 1

Country Status (19)

Country	Link
US (3)	US7744888B2 (de)
EP (2)	EP1411982B1 (de)
JP (3)	JP4815101B2 (de)
KR (1)	KR100850731B1 (de)
CN (2)	CN101045161B (de)
AT (2)	ATE411045T1 (de)
AU (1)	AU2002305041B2 (de)
CA (1)	CA2428822C (de)
CY (2)	CY1108701T1 (de)
DE (1)	DE60229394D1 (de)
DK (2)	DK1985634T3 (de)
ES (2)	ES2316569T3 (de)
IL (4)	IL160168A0 (de)
MX (1)	MXPA04001047A (de)
NO (2)	NO333456B1 (de)
NZ (1)	NZ531199A (de)
PT (2)	PT1985634E (de)
TW (1)	TWI327070B (de)
WO (1)	WO2003013603A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7744888B2 (en) *	2001-08-03	2010-06-29	Abgenomics Cooperatief U.A.	Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) *	2001-08-03	2004-06-17	Rong-Hwa Lin	Modulators of P-selectin glycoprotein ligand 1
BRPI0414402A (pt) *	2003-09-15	2006-11-14	Abgenomics Corp	moduladores de ligante 1 de glicoproteìna p-selectina
EP1689776A2 (de) *	2003-11-12	2006-08-16	Wisconsin Alumni Research Foundation	Equiner p-selectin-glycoproteinligand-1 und anwendungen dafür
UY28886A1 (es) *	2004-05-10	2005-12-30	Boehringer Ingelheim Int	Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
AU2012201999C1 (en) *	2004-05-10	2016-05-12	Abgenomics Cooperatief U.A.	Antibodies
ES2655833T3 (es) *	2004-05-11	2018-02-21	AbGenomics Coöperatief U.A.	Epítopos que inducen la muerte de células T
WO2007033959A2 (en) *	2005-09-19	2007-03-29	Vib Vzw	Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
US20070160601A1 (en) *	2005-12-09	2007-07-12	Angela Widom	Neutralizing antibodies against primate psgl-1 and uses therefor
US7833530B2 (en) *	2008-05-15	2010-11-16	Selexys Pharmaceuticals Corporation	Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies
ES2387156B1 (es) *	2010-12-01	2013-07-04	Universidad Autónoma de Madrid	Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
EP2718325A4 (de)	2011-06-13	2015-03-11	ABGENOMICS COöPERATIEF U A	Anti-psgl-1 antikörper und verwendungen davon
PT3166636T (pt)	2014-07-08	2021-06-29	Sanford Burnham Med Res Inst	Moduladores de psgl-1 e utilizações dos mesmos
IL260289B (en)	2016-01-08	2022-08-01	Bioalliance Cv	Tetravalent anti-psgl-1 antibodies and uses thereof
US20170241415A1 (en) *	2016-02-19	2017-08-24	Muzan, Inc.	Sanitary check valve
KR20250159733A (ko)	2017-01-11	2025-11-11	브리스톨-마이어스 스큅 컴퍼니	Psgl-1 길항제 및 그의 용도
PE20250933A1 (es)	2017-03-14	2025-04-02	Five Prime Therapeutics Inc	Anticuerpos de union a vista a ph acido
BR112020019083A2 (pt)	2018-03-21	2020-12-29	Five Prime Therapeutics, Inc.	Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
PE20210687A1 (es)	2018-07-11	2021-04-08	Bristol Myers Squibb Co	Anticuerpos de union a vista a ph acido
CN112740043A (zh)	2018-07-20	2021-04-30	皮埃尔法布雷医药公司	Vista受体
WO2020224450A1 (en) *	2019-05-03	2020-11-12	The University Of Hong Kong	Method for peritoneal metastatic cell detection and isolation thereof
CA3141334A1 (en)	2019-06-04	2020-12-10	Verseau Therapeutics, Inc.	Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
WO2025168211A1 (en) *	2023-02-10	2025-08-14	Novo Nordisk A/S	P-selectin peptide ligands

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2002A (en) *		1841-03-12		Tor and planter for plowing
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4704692A (en)	1986-09-02	1987-11-03	Ladner Robert C	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5464778A (en) *	1989-03-08	1995-11-07	Board Of Regents Of The University Of Oklahoma	Glycoprotein ligand for P-selectin and methods of use thereof
US5378464A (en) *	1989-03-08	1995-01-03	Board Of Regents Of The University Of Oklahoma	Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5690933A (en) *	1989-05-31	1997-11-25	Glaxo Wellcome Inc.	Monoclonal antibodies for inducing tolerance
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5709859A (en) *	1991-01-24	1998-01-20	Bristol-Myers Squibb Company	Mixed specificity fusion proteins
US6124267A (en) *	1991-02-05	2000-09-26	Southpac Trust Internationals, Inc.	O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) *	1991-02-05	2001-10-30	The Board Of Regents Of The University Of Oklahoma	Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) *	1991-05-06	1999-10-26	The Regents Of The University Of California	Assays for inhibitors of leukocyte adhesion
US5843707A (en) *	1992-10-23	1998-12-01	Genetics Institute, Inc.	Nucleic acid encoding a novel P-selectin ligand protein
WO1994014836A1 (en) *	1992-12-18	1994-07-07	Centocor, Inc.	Peptide inhibitors of selectin binding
DE69415154T2 (de) *	1993-01-25	1999-07-29	Dana-Farber Cancer Institute, Inc., Boston, Mass.	Chimäre selektine erhältlich durch domänenaustauch und ihre verwendungen
WO1995014787A1 (en) *	1993-11-22	1995-06-01	Centocor, Inc.	Peptide inhibitors of selecting binding
US5686426A (en) *	1994-11-17	1997-11-11	Bristol-Myers Squibb Company	Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
KR100523506B1 (en)	1995-08-03	2005-10-24		Peptide and O-glycan inhibitors of selectin mediated inflammation
JPH09227410A (ja)	1996-02-21	1997-09-02	Sumitomo Pharmaceut Co Ltd	臓器移植拒絶反応の抑制剤
WO1999043353A2 (en) *	1998-02-26	1999-09-02	Boehringer Ingelheim Pharmaceuticals, Inc.	Combination anti-selectin and immunosuppressant therapy
CA2347119A1 (en)	1998-10-30	2000-05-11	Genetics Institute, Inc.	Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
US20040002450A1 (en) *	2000-12-29	2004-01-01	Janette Lazarovits	Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
EP1406930A4 (de)	2000-12-29	2007-01-10	Savient Pharmaceuticals Inc	"isolierte moleküle mit sulfatierte gruppierungen enthaltenden epitopen, antikörper gegen solche epitope und verwendungen davon"
US20040001839A1 (en) *	2000-12-29	2004-01-01	Avigdor Levanon	Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7744888B2 (en)	2001-08-03	2010-06-29	Abgenomics Cooperatief U.A.	Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) *	2001-08-03	2004-06-17	Rong-Hwa Lin	Modulators of P-selectin glycoprotein ligand 1
US20050152906A1 (en) *	2003-06-30	2005-07-14	Avigdor Levanon	Specific human antibodies
UY28886A1 (es)	2004-05-10	2005-12-30	Boehringer Ingelheim Int	Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
ES2655833T3 (es)	2004-05-11	2018-02-21	AbGenomics Coöperatief U.A.	Epítopos que inducen la muerte de células T
EP2718325A4 (de)	2011-06-13	2015-03-11	ABGENOMICS COöPERATIEF U A	Anti-psgl-1 antikörper und verwendungen davon

2002
- 2002-01-18 US US10/051,497 patent/US7744888B2/en not_active Expired - Fee Related
- 2002-03-13 IL IL16016802A patent/IL160168A0/xx active IP Right Grant
- 2002-03-13 AT AT02733839T patent/ATE411045T1/de active
- 2002-03-13 DE DE60229394T patent/DE60229394D1/de not_active Expired - Lifetime
- 2002-03-13 ES ES02733839T patent/ES2316569T3/es not_active Expired - Lifetime
- 2002-03-13 JP JP2003518607A patent/JP4815101B2/ja not_active Expired - Fee Related
- 2002-03-13 DK DK08012718.6T patent/DK1985634T3/da active
- 2002-03-13 PT PT08012718T patent/PT1985634E/pt unknown
- 2002-03-13 PT PT02733839T patent/PT1411982E/pt unknown
- 2002-03-13 CN CN200710003904XA patent/CN101045161B/zh not_active Expired - Fee Related
- 2002-03-13 EP EP02733839A patent/EP1411982B1/de not_active Expired - Lifetime
- 2002-03-13 AT AT08012718T patent/ATE531734T1/de active
- 2002-03-13 EP EP08012718A patent/EP1985634B1/de not_active Expired - Lifetime
- 2002-03-13 NZ NZ531199A patent/NZ531199A/en not_active IP Right Cessation
- 2002-03-13 CN CNB028029844A patent/CN1304051C/zh not_active Expired - Fee Related
- 2002-03-13 DK DK02733839T patent/DK1411982T3/da active
- 2002-03-13 WO PCT/US2002/007498 patent/WO2003013603A1/en not_active Ceased
- 2002-03-13 KR KR1020047001711A patent/KR100850731B1/ko not_active Expired - Fee Related
- 2002-03-13 AU AU2002305041A patent/AU2002305041B2/en not_active Ceased
- 2002-03-13 CA CA2428822A patent/CA2428822C/en not_active Expired - Lifetime
- 2002-03-13 ES ES08012718T patent/ES2376948T3/es not_active Expired - Lifetime
- 2002-03-13 MX MXPA04001047A patent/MXPA04001047A/es active IP Right Grant
- 2002-04-10 TW TW091107216A patent/TWI327070B/zh not_active IP Right Cessation
2004
- 2004-02-02 IL IL160168A patent/IL160168A/en unknown
- 2004-02-02 NO NO20040460A patent/NO333456B1/no not_active IP Right Cessation
2008
- 2008-03-07 JP JP2008058501A patent/JP2008260759A/ja not_active Abandoned
2009
- 2009-01-13 CY CY20091100020T patent/CY1108701T1/el unknown
- 2009-06-29 US US12/494,018 patent/US8298540B2/en not_active Expired - Fee Related
2010
- 2010-02-18 IL IL204030A patent/IL204030A/en active IP Right Grant
2011
- 2011-01-11 IL IL210557A patent/IL210557A0/en unknown
2012
- 2012-02-01 CY CY20121100115T patent/CY1112966T1/el unknown
- 2012-02-03 JP JP2012022511A patent/JP2012092144A/ja active Pending
- 2012-09-14 US US13/616,749 patent/US8557579B2/en not_active Expired - Fee Related
2013
- 2013-01-14 NO NO20130069A patent/NO334850B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO20130069L (no)	2004-02-24
US20090304709A1 (en)	2009-12-10
WO2003013603A1 (en)	2003-02-20
CY1112966T1 (el)	2016-04-13
NZ531199A (en)	2004-11-26
IL160168A0 (en)	2004-07-25
WO2003013603A8 (en)	2004-06-10
CY1108701T1 (el)	2014-04-09
IL204030A (en)	2014-11-30
US8298540B2 (en)	2012-10-30
CN1304051C (zh)	2007-03-14
US20030049252A1 (en)	2003-03-13
US8557579B2 (en)	2013-10-15
NO20040460L (no)	2004-02-24
KR20040054670A (ko)	2004-06-25
PT1411982E (pt)	2008-12-24
IL160168A (en)	2011-02-28
JP2012092144A (ja)	2012-05-17
EP1985634A1 (de)	2008-10-29
CA2428822C (en)	2014-10-28
ATE411045T1 (de)	2008-10-15
EP1985634B1 (de)	2011-11-02
KR100850731B1 (ko)	2008-08-06
IL204030A0 (en)	2011-08-01
CN101045161B (zh)	2010-06-16
EP1411982B1 (de)	2008-10-15
HK1124624A1 (en)	2009-07-17
CN1473052A (zh)	2004-02-04
JP2004521958A (ja)	2004-07-22
IL210557A0 (en)	2011-03-31
ES2316569T3 (es)	2009-04-16
NO333456B1 (no)	2013-06-10
JP4815101B2 (ja)	2011-11-16
ES2376948T3 (es)	2012-03-21
US20130011861A1 (en)	2013-01-10
PT1985634E (pt)	2012-02-07
DE60229394D1 (en)	2008-11-27
US7744888B2 (en)	2010-06-29
AU2002305041B2 (en)	2005-11-10
CN101045161A (zh)	2007-10-03
JP2008260759A (ja)	2008-10-30
DK1411982T3 (da)	2009-02-16
EP1411982A4 (de)	2004-10-06
TWI327070B (en)	2010-07-11
EP1411982A1 (de)	2004-04-28
CA2428822A1 (en)	2003-02-20
NO334850B1 (no)	2014-06-16
MXPA04001047A (es)	2005-02-17
DK1985634T3 (da)	2012-02-20
HK1065489A1 (en)	2005-02-25

Publication	Publication Date	Title
ATE531734T1 (de)	2011-11-15	Antikörper gegen p-selectin-glycoproteinliganden 1 (psgl-1) zur behandlung allergischer erkrankungen
ATE416610T1 (de)	2008-12-15	Wasserfilter
WO2005027831A3 (en)	2005-12-01	Modulators of p-selectin glycoprotein ligand 1
WO2004043361A3 (en)	2007-10-04	Compositions and methods for the treatment of natural killer cell related diseases
ATE483472T1 (de)	2010-10-15	Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
DE60135498D1 (de)	2008-10-02	Produktion von ganzen Antikörpern in prokaryontischen Zellen
ATE404196T1 (de)	2008-08-15	Rapamycin und il-10 zur behandlung von autoimmunerkrankungen
RU2599417C3 (ru)	2017-11-28	Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
AR043616A1 (es)	2005-08-03	Anticuerpos contra receptor humano il-21 y usos de los mismos
DE60139689D1 (de)	2009-10-08	Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
EA200700175A1 (ru)	2007-08-31	Композиции и способы лечения воспалительных заболеваний
EP1660128A4 (de)	2009-01-21	Anti-fcrn-antikörper zur behandlung von auto/allo-immunzuständen
ATE346088T1 (de)	2006-12-15	Kristallisierbare zusammensetzungen, die einen komplex von protease-domäne ns3 und ns4a aus dem hepatitis c virus enthalten, und damit bereitgestellte kristalle
TW200607863A (en)	2006-03-01	Immune modulating compounds from fungi
ATE439851T1 (de)	2009-09-15	Verwendung probiotischer bakterien zur behandlung von infektionen
EP1501465A4 (de)	2006-04-19	Vektoren mit beiden isoformen von beta-hexosaminidase
DE60042941D1 (de)	2009-10-22	Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten
ATE343398T1 (de)	2006-11-15	Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
DE60313803D1 (de)	2007-06-21	Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
TW200513262A (en)	2005-04-16	Modulators of P-selectin glycoprotein ligand 1
CA99898S (en)	2003-05-07	Filter for aquariums
ATE146967T1 (de)	1997-01-15	Verwendung von ifn-gamma zur behandlung von infektionen bei transplantatenempfängern
ATE373477T1 (de)	2007-10-15	Cci-779 zur behandlung von mantelzelllymphom
DE60304678D1 (de)	2006-05-24	Idraparinux (sanorg 34006) zur behandlung und sekundärprophylaxe von thromboembolien bei patienten mit tiefer venenthrombose
DE602004019696D1 (de)	2009-04-09	Die multiple resistenz von pflanzen gegen phytopathogene und schädlinge induzierende proteine